• No results found

The Clinical Value of HDL Function Measurements

N/A
N/A
Protected

Academic year: 2021

Share "The Clinical Value of HDL Function Measurements"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

The Clinical Value of HDL Function Measurements Ebtehaj, Sanam

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Ebtehaj, S. (2019). The Clinical Value of HDL Function Measurements. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 28-06-2021

(2)

7

(3)

140

(4)

CHAPTER 7

Summary

(5)

Chapter 7

Summary

Cardiovascular diseases (CVD) are the leading causes of morbidity and mortality worldwide.

Dyslipidemia, which is characterized by increased low-density lipoprotein cholesterol (LDL-C) and triacylglycerols, and decreased high-density lipoprotein cholesterol (HDL-C), is an important risk factor for development of CVD. Several epidemiological studies showed an inverse relationship between plasma HDL-C levels and risk of atherosclerosis. However, raising HDL-C levels pharmacologically was reported to be not clinically beneficial and failed to reduce cardiovascular risk. Therefore, Improved HDL functionality was suggested to be a better measure for risk of CVD.

HDL protects the blood vessels against the development of atherosclerosis through several mechanisms. Most importantly, HDL mediates cholesterol efflux from lipid-laden macrophages in the arterial wall, which is considered as the initial step in the reverse cholesterol transport (RCT) pathway. This process returns peripheral cholesterol to the liver for its final excretion into the bile and is believed to be the primary anti-atherogenic action of HDL. Several epidemiological studies demonstrated a strong inverse relationship between HDL cholesterol efflux capacity and prevalence as well as incidence of coronary artery disease (CAD). Additional anti-atherogenic functions of HDL include anti-oxidative properties, mediated by HDL’s ability to inhibit the oxidative modification of LDL, and anti-inflammatory properties, referring to the capacity of HDL to reduce cytokine-induced expression of adhesion molecules on endothelial cells.

Several studies have indicated that in certain disease conditions, such as renal failure and diabetes, HDL can lose its anti-atherosclerotic functions and may even become pro- atherogenic. However, the relationships between HDL functionality and cardiovascular risk are still poorly understood. Therefore, the research presented in this thesis focused on the importance of HDL functionality measurements for cardiovascular risk.

Chapter 2 examined HDL cholesterol efflux capacity as a predictive measure for cardiovascular risk in patients with type 2 diabetes on hemodialysis who participated in the 4D study. It is known that HDL cholesterol efflux capacity inversely correlates with atherosclerotic CVD in individuals with normal kidney function. However, the results of this chapter indicated that HDL cholesterol efflux capacity is not a prognostic predictor of cardiovascular risk in diabetic patients on hemodialysis.

In chapter 3, it has been determined whether anti-oxidative activity of HDL would be associated with incident cardiovascular mortality, all-cause mortality, and graft failure in renal transplant recipients (RTR), a population with accelerated development of atherosclerosis. The result of this prospective study demonstrated that anti-oxidative capacity of HDL does not predict cardiovascular or all-cause mortality in RTR. However, HDL’s anti-oxidative function was associated with graft failure, which was lost when adjusting for renal function and inflammatory load.

In chapter 4, the anti-inflammatory function of HDL was studied in type 2 diabetes and factors that may potentially impact this metric of HDL functionality were explored. The results of this chapter showed that HDL anti-inflammatory capacity is substantially impaired in T2DM, partly attributed to hyperglycemia, decreased PON-1 activity, and low-grade chronic inflammation.

Decreased anti-inflammatory capacity of HDL may contribute to increased risk of

142

(6)

Summary

atherosclerosis in patients with type 2 diabetes.

The study described in chapter 5 tested associations between individual or combined HDL functionalities with PROCAM-risk, intima media thickness, and Agatston score as risk measures of CVD in patients with high estimated cardiovascular risk. The results of this cross-sectional study revealed that no association exists between these measures of HDL function and PROCAM risk in this patient population.

Finally, chapter 6 summarizes and discusses the highlights of our studies in this thesis. Taken together, important information may be obtained by looking into alternative ways to measure HDL functionality beside plasma levels of HDL cholesterol.

(7)

Chapter 7

ﺑﯿ ــﺎ ر ی ﻠﺒ ــ و ﻗــ ﻠــ ا ــﻠ ــ گ و ﯿــ ا ــﺎ د ر ا ــ ــﺎ ن ــ ب ــ ــ د . د د ﯾــ ﯿﭙ ﯿــ ــﺎ

اﻧ ــ ا ع ﺘﻠ ﻔـ ـ ا از ــ دل ر ــ و ــ ز ﺑـ ـ ھ ــ ــ ــ ــ ر ﻓـ ـﺘ ﯿـ ـ ا ن ــ و ل LDL ، ــ ی

ﻠﯿ ــ ھ و ــﺎ ھ ﯿــ ا ن ــﺘ و ل HDL ــ ــ . د اﯾ ــ ا ــﺘ ل ــﺒ ــ و ــ ــ دن ﯾــ ا ر ه ــ و ق ــ

د ا ز ا د ر CVD ا .

ــﺘ و ل ــ ا از ﻧــ ا ع ــ ﺑــ ﯿــ ﺎﺑ ــ ــ د ر ــ ن ــ ــ ــ ــ ھ ــﯿ د ﻟﯿ ــ ــ ﯿﭙ ــ و ﺗﺌ ﯿ ھ دــﺎ ر

ــ ن ھ ــ ــ ــ . ﻟﯿ ﭙــ و ﺗﺌ ﯿ ھ ــﺎ ی ــ ــﺎ ل LDL اﻧ ــ ه ــ او ــ ﯿــ ا ان ﯾــ ﯿﭙ ــ و ﺗﺌ ﯿ ز ﯾــ د ــ

ا ر ه ر گ ھ ر ب د ه و ا ا آد .د

ر ــ ب ﺑـ ـ د ر ر گ ھ ــ ــ ــ ص ر گ ھ ــ ی و ﻧـ ـ ی ــ ﯿ ــ ر ی ھ ــ ی ﻠﺒ ــ ر ا ــ ــ ﻨـ . ـﺪ HDL

ﻟﯿ و ﺗﺌ ﯿ ھ ــﺎ ــﺎ ــﺎ ــﺎ ــ ــﻨ ــ ﺑــ ر اا ز ــﻠ ل ھ دــﺎ و ر ــ د ه و ــ ا ی ــ د ﻓــ ــ ﺒــ ﻧــ .

ﺎﻟ ــ ات ﭘﯿ ــ ﯿ ژ ــ دن ا د ه ــ ر اﺑ ــ ــ ــ ﯿ ــ و ل HDL و ــ آ و ــ و ز و ــ دد ا ر د

او ﻧـ ـﺪ ا ز ه ﯿ ی ــ ــ و آل دن ر ــ دن ر ــ ﯿ ﯿﻨ ــ ــ ﯿ ــ ر ی ھ ــ ی ﻠﺒ ــ ر و ش ﻔﯿ ــ ای ــ . ﺑـ اـﺎ ﯾـ ـ

ــ ل ا، ﻓـ ـ اﯾ ــ و ل HDL ا ز ــ د ا ر و ﯾـ ـ ا ز ــ ظ ــ ﺎﻟ ﯿﻨ ﻔﯿ ــ ﯿ ــ و ــ ــ ھ ــ ا ﺑـ ـﺘ ــ ﯿ ــ ر ی

ﻗﻠ ﺒـ ـ و و ﻗـ ـ ــ ــ ﻨـ .ﺑ ـﺪ ﻨـ ـﺎ ــ اﯾ ا ﯿـ ـ ا اً،

ﻧـ ـﺪ ا ز ه ﯿ ی ــ د HDL ــ ﻨـ ـ ا ن ﯿـ ـﺎ ر ی ﺘـ ـ ــ ا ی

ﭘﯿ ﺑﯿ ا ﺑﺘ CVD ح اه .

HDL ا ز ر ــ ب ــ و دل ر ر گ ھ ــ ﻠــ ﯿ ی ــ ﻨـ ـﺪ و ﺘـ ـ ــ ــ آف ان دز ﯾـ ـ ا ر ه ر گ ھ ــ ــ ــ د و

اﯾ ــ ــ اد ز ط ﯾـ ـ ﻨــ ﺎﻧ ﯿ ــ ا ــ م ــ ــ د او ﯾـ ـ ﺎﻧ ﯿ ــ ﺎﻓ ــ ﻨﻨ ــ آ دــﺎ ر اﺑ ــ ﯿ ــ ر ی

ھ ـــ ی ﻠﺒ ـــ و و ﻗـ ــ ـــ ـــ . ﺘـ ــ ﺎﻧ ﯿ ـــ ـــ د HDL ا، ﯾﻔ ـــ ـــ و ال ز و ﻓﺎ ژ ھ ـــ دی ر و ن

د ﯾــ ا ر ه ــ ﯾﺎ ا ــ ــ ــ ﻨــ ا ن ــﺎ ام و ﻟﯿ ــ د ر ــﯿ ا ﻧﺘ ﻘــ ل ــﺘ و ل ــ س RCT ــﻨ ــ ــ . د د ار ﯾــ

اﯾ HDL ، و ل ﯿ ر ا در ﺎﯾ ا،

ز د اﻧ .

ﺎﻟ ــ ات ﭘﯿ ــ ﯿ ژ ــ ن د ھ ــ ــ ر اﺑ ــ ــ س ــ ی ــ ﯿ ــ و ال ﯾﻔ ــ HDL و ــ ﯿ ع و ــ و ز

ﺑﯿ ــ ر ی ھ ــ ی ــ و ق و ﻧـ ـ CAD و ــ دد ا ر . د ا دز ــ ــ د ھ ــ ی HDL ، و ــ ﺿ ــ ا ــ ﯿ اﺗ ﯿ ا ــ ــ

اﻧ ــ ﺎﯾ آ ن ــ ا ی ــ ر ــ د ن و ﻠـ ـ ﯿ ای از ــ ﯿ ه ــ ن LDL ﻔﺘ ــ ــ د دو ــ ی و ــ ﺿ ــ ا ﻟﺘ ــ ﺎﺑ

ا اﻧ ﺎﯾ آ ن ر ھ ا ﻨﻔ ﯿﺘ ﯿ ھ ل ھ ای و ﺗﻠ ﯿﺎ ال .

ا ز ــ دی ــ ، ﺎﻟ ــ ت ــ د ی ــﺎ دن ا د اه ﻧـ ـﺪ ــ د ر ــ اﯾ ــ ﺎﻧ ﻨــ ر ــﺎ ﻠﯿ ــ دو ﯾﺎ ﺑــ HDL ــ

اﻧ ــ ــ د ﺿ ــ آ و ــ و ز ــ د ر اا دز ــ ھ ــ و ﺘــ ــ ا ــ ــ آ و ــ و ز ر اا ﻓــ اﯾ د ھ ــ .

ﺑــ ا ﯾــ ــﺎ ل ر اﺑ ــ ــﯿ ــ د HDL و ــ ﻠﺒ ــ و و ﻗــ ھ ﻨــ ز ــ ر ــ ﺎﻟ ــ ــ اه ــ و ﻨــ ﺎﺑ ا ﯾــ

ﭘــ و ھ ھ ــﺎ ای ﯾــ ﺎﯾ ــﺎ ن ــ ــ ا ھ ﯿــ ا ﻧــ ا ز ه ﯿــ ی اﻧ ــﺎ و ــ HDLد ــ ا ی ــ ﻠﺒ ــ و و ﻗــ ــ

د ا ر .د

د ر ــ د و ام از ﯾــ ﺎﯾ ــﺎ ن ــ ، اﻧ ــﺎ HDL ــ ا ای ﯾﻔ ــ ــﺘ و ل ــ ﻨــ ا ن ــﯿ ﯿﻨ ــ ﻨﻨ ــ ه ﯿ ــﺎ ر ی ﻠﺒ ــ

و و ﻗـ ـ د ر ﯿ ــ ر ا ن ﺒـ ـﺘ ــ د ﯾﺎ ﺑـ ـ ــ ع ٢ و ھ د ﯾـ ـﺎ ﻟﯿ ــ د ر ﺎﻟ ــ 4 D ــ د ا ــ ﺘﻨ ، ــ ر د ر ــ

ﻗــ ا ر ﻓﺘ ــ ا ــ . د ار ﻓــ ا د ــﺎ ــ د ط ﺒﯿ ــ ﻠﯿ ــ ، اﻧ ــﺎ ا ﯾﻔ ــ ــﺘ و ل HDL ا، ر ﺗﺒ ــﺎ ط ــ س ــﺎ CVD

ھ ــﺎ آی و ــ و ز د ا ر د ، اــﺎ ﯾـ ـ ــﺎ ل ﺘـ ـﺎ ا ﯾــ ــ ــﺎ دن ا د اه ــ ــ اﻧ ــ ﺎﯾ ا ﯾﻔ ــ ــ و ل HDL ،

ﭘﯿ ﯿﻨ ﻨﻨ ه دی ﻗﯿ ا ی ﯿ ر ی ﻠﺒ و و د ر ﯿ ر ا دن ﯾﺎ ﺑﺘ ھ اه ھ د ﯾﺎ ﻟﯿ ﯿ .

د ر ــ ــ م اﻧ ــ ﺎﯾ ﺿ ــ ا ــ ﯿ اﺗ ﯿ HDL ــ ــ ﯿ ع ــ گ و ﯿـ ـ و ر ــ ﺎﯾ ﯿ ﻧـ ـﺪ ﻠﯿ ــ د ر ﯿ ــ ر ا دن ر ﯾـ ـﺎ ﻓﺘ

ﭘﯿ ﻧـ ـﺪ ﻠﯿ ــ ــ ر د ر ــ ــ ا ر ﻓﺘ ــ ا ــ . ﺘـ ـﺎ ا ﯾـ ـ ﺎﻟ ــ آ ﯾﻨ ــ هﻧ ــ دن ا د اه ــ ــ اﻧ ــ ﺎﯾ ﺿ ــ

ا ــﯿ اﺗ ﯿ HDL اﻧ ــ ــ گ و ﯿــ ــ ا ز ﯿ ــﺎ ر ی ﻠﺒ ــ و و ﻗـ ـ ر دا ر ﯿ ــﺎ ر ا ن ﯿ ﻧــ ﻠﯿ ــ ــﺎ دن ھ ــ . ﺑــ

اﯾ ــ ــﺎ ل ، ر اﺑ ــ ا ی ــﯿ ا ﯾــ ــ HDLد ــﺎ ــ ز د ن ﯿ ﻧــ ﻠﯿ ــ و ــ دد ا ــ ــ دــﺎ ر ــ ــ ﻓﺘ ــ د

ﻠﯿ و ر ھ ای ﻟﺘ ﺎﺑ ا ر اﺑ ا ز ﯿ ر .

د ر ــ ــ ر م ، ــ د ﺿ ــ ا ﻟﺘ ــ ﺎﺑ HDL د ر ﯿ ــ ر ا دن ﯾﺎ ﺑـ ـ ــ ع ٢ و ا ــ ــ ــ ا ﯾـ ـ ﯿـ ـﺎ ر د

ــ ر د ر ــ ــ ا ر ﻓــ . ﻧﺘ ــﺎ ا ﯾــ ــ ــﺎ دن ا د ــ ــ د ﺿ ــ ا ﻟﺘ ــﺎ HDL ــ ط ــ ر ﺎﺑ ــ ــ ا ی

د ر ﯿ ـــ ر ا دن ﯾﺎ ﺑـ ــ ـــ ع ٢ ﺿ ـــ ﯿ ا ـــ ـــ ـــ ا آز ن ـــ ا ﻓـ ــ اﯾ ھ ﯿﭙ ﻠﯿ ـــ ، ـــ ھ PON1 او ﻟﺘ ـــ ب

ـــ ﺑـ ــ ط ـــ ـــ . اﯾ ـــ ـــ ھ اﻧ ـــ ﺎﯾ ﺿ ـــ ا ﻟﺘ ـــ ﺎﺑ HDL ـــ ا ـــ ـــ ا ﻓـ ــ اﯾ ـــ ا ﺑـ ــﺘ ـــ

144

Referenties

GERELATEERDE DOCUMENTEN

DE FACTORANALYSE. De factoranalyse is een methode om zonder veronderstellingen deelaspecten van een probleem te bestuderen. Op een geheel objectieve wijze wordt

validation of a novel right-sided heart failure model after implantation of continuous flow left ventricular assist de- vices: the EUROMACS (European registry for patients

HDL function measurements provide clinical information independent of established cardiovascular risk metrics - a cross-sectional study from the PROCAM-CT cohort.

Patients with end-stage renal disease are at high cardiovascular risk, which cannot be fully explained by traditional risk factors. HDL cholesterol efflux capacity is not a

So although the classifiers used by MVPA methods are able to successfully discriminate experimental conditions based on the measured neural patterns of activity, it remains unclear

Indien dit niet mogelijk is, biedt de Leerplichtwet alleen de mogelijkheid dat het kind helemaal niet meer naar school gaat of dat hij en zijn ouders of verzorgers

De eisen die aan de onderwerping van de Saksen gelegd werden, waren volgens Einhard, hofschrijver van Karel de Grote, dan ook ‘[…] het afzweren van het aanbidden van demonen en

Er is immers sprake van staatssteun wanneer een belastingplichtige bevoordeeld wordt, hetgeen het geval is wanneer dat wat in een ruling wordt bepaald niet de uitkomst zou zijn